Introduction: We describe five patients receiving a re-implantation (RI) after post-operative dosimetry of the primary 125-I permanent prostate brachytherapy (BT) for prostate cancer revealed an insufficient dose coverage.
Materials And Methods: Five out of 222 consecutive patients treated (from March, 2001 to August, 2012) with 125-I BT, received a RI after dosimetric verification by CT and MRI fusion four to eight weeks after implantation displayed an insufficient dose coverage. RIs were performed with 10 to 19 seeds, three to four months after primary intervention. Dosimetry after RI showed an improved and sufficient total dose coverage in all patients.
Results: At last follow-up (18 to 99 months, median 57 months), none of the patients had relevant implant associated side-effects. Functional outcome was comparable to patients after one-time implantation. PSA levels post intervention showed a decreasing tendency in 4 patients. One patient had a local recurrence after 12 months.
Conclusion: In our series, approximately 2% of the patients treated with permanent prostate BT required a RI due to insufficient dose coverage. None of the patients who underwent RI experienced complications. Our series, although only with 5 cases and limited follow-up, along with other published reports, demonstrates good tolerability.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851561 | PMC |
| http://dx.doi.org/10.1186/1748-717X-8-194 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Haralick texture feature analysis for Monte Carlo dose distributions of permanent implant prostate brachytherapy.
Brachytherapy
November 2024
Carleton Laboratory for Radiotherapy Physics, Physics Department, Carleton University, Ottawa, Ontario, Canada. Electronic address:
Purpose: Demonstrate quantitative characterization of 3D patient-specific absorbed dose distributions using Haralick texture analysis, and interpret measures in terms of underlying physics and radiation dosimetry.
Methods: Retrospective analysis is performed for 137 patients who underwent permanent implant prostate brachytherapy using two simulation conditions: "TG186" (realistic tissues including 0-3.8% intraprostatic calcifications; interseed attenuation) and "TG43" (water-model; no interseed attenuation).
Predictors of corporo-venocclusive dysfunction in men with bilateral nerve-sparing radical prostatectomy.
J Sex Med
January 2025
Sexual & Reproductive Medicine Program, Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States.
Article Synopsis
- Erectile dysfunction (ED) can occur in men who have had bilateral nerve-sparing surgery, with corporo-venocclusive dysfunction (CVOD) being a primary cause of permanent ED after radical prostatectomy (RP).
- A study examined comorbidity factors linked to CVOD in men without prior ED who underwent RP, finding significant associations with increased age and obstructive sleep apnea (OSA).
- The research highlights that comorbidities, particularly OSA, influence recovery of erectile function post-surgery; however, the findings may not apply broadly to all patients, as the study focused on men already seeking treatment for ED.
Current status of the working environment of brachytherapy in Japan: a nationwide survey-based analysis focusing on radiotherapy technologists and medical physicists.
J Radiat Res
December 2024
Department of Radiology, University of Yamanashi Faculty of Medicine, 1110 Shimokato, Chuo-shi, Yamanashi 409-3898, Japan.
Article Synopsis
- Brachytherapy (BT), particularly high dose rate (HDR) BT, has become more complex due to advanced techniques, necessitating significant training for radiotherapy technologists and medical physicists (RTMPs).
- A survey conducted across 837 radiation treatment facilities in Japan revealed varying working times for HDR procedures and low quality control (QC) implementation rates for BT compared to external beam radiation therapy (EBRT).
- The findings underscore a need for improved training and education for RTMPs to enhance the quality and safety of BT practices in Japan.
Recent Advancements in Prostate Catheters and Stents for Management of Benign Prostatic Hyperplasia.
Curr Urol Rep
October 2024
Department of Urology, Northwell Health, Manhasset, NY, USA.
Purpose Of Review: The prevalence of benign prostatic hyperplasia (BPH) is rising, however, current treatment options present severe complications and limit patient's quality of life. Accordingly, advancements in prostatic catheter and stent designs for use in treating lower urinary tract symptoms (LUTS) in BPH patients have largely expanded in the past five years and we aim to provide an exhaustive summary of recent outcomes.
Recent Findings: The dual dilation and paxlitaxel eluting Optilume BPH Catheter System enhances promise in catheter-based treatments, providing the longest sustained increase in max urinary flow rate and decrease in post-void residual volume compared to alternative MISTs.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!